Zobrazeno 1 - 10
of 169
pro vyhledávání: '"Stephan D. Voss"'
Autor:
Gabrielle C. Colleran, Neha Kwatra, Leah Oberg, Frederick D. Grant, Laura Drubach, Michael J. Callahan, Robert D. MacDougall, Frederic H. Fahey, Stephan D. Voss
Publikováno v:
Cancer Imaging, Vol 17, Iss 1, Pp 1-15 (2017)
Abstract PET/CT plays an important role in the diagnosis, staging and management of many pediatric malignancies. The techniques for performing PET/CT examinations in children have evolved, with increasing attention focused on reducing patient exposur
Externí odkaz:
https://doaj.org/article/debc54600b354ccca20aa8a3ee31bca0
Autor:
Matthew Barth, Mitchell S Cairo, Megan S Lim, Lauren Harrison, Chitti Moorthy, Saro Armenian, Kayleigh Klose, Jessica C Hochberg, Jaclyn Baso, Ana C Xavier, Anthony N Audino, Rodney Miles, Samir Kahwash, Stephan D Voss, Suzanne Braniecki, Matthew Ehrhardt, Arvind Budhram, Ariel Stonberg, Stanton Goldman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/b0bb9153ea8f4222a059f4baf9ebf78f
Autor:
Keri A. Streby, Marguerite T. Parisi, Barry L. Shulkin, Brian LaBarre, Rochelle Bagatell, Lisa Diller, Stephan A. Grupp, Katherine K. Matthay, Stephan D. Voss, Alice L. Yu, Wendy B. London, Julie R. Park, Gregory A. Yanik, Arlene Naranjo
Publikováno v:
Pediatric Blood & Cancer.
Autor:
Hina Shah, Reethy Sundar, David E. Arboleda Prado, Jian W. Dong, David Z. Chow, Braden Kuo, Stephan D. Voss, Heather A. Jacene, Matthew S. Robertson, Thomas S. C. Ng
Publikováno v:
Digestive Diseases and Sciences. 68:541-553
Autor:
Brenda J. Weigel, Susan M. Blaney, Stacey L. Berg, Stephan D. Voss, Mark Krailo, Donald A. Barkauskas, David Hall, Malcolm A. Smith, Peter J. Houghton, Richard B. Lock, Hernan Carol, Stephanie L. Safgren, Joel M. Reid, David T. Teachey, Elizabeth Fox, Yael P. Mossé
Purpose:Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a potent and selective AAK inhibitor. In pediatric preclinical models, antitumor acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f1dc91e84c94f88674693e3c59af6cb
https://doi.org/10.1158/1078-0432.c.6527514.v1
https://doi.org/10.1158/1078-0432.c.6527514.v1
Autor:
Brenda J. Weigel, Elizabeth Fox, Joel M. Reid, Stacey L. Berg, Stephan D. Voss, Daphne A. Haas-Kogan, John M. Maris, Bruce R. Pawel, Charles G. Minard, Xiaowei Liu, Heba Ijaz, Rachel A. Kudgus, Sharmistha Pal, Kristina A. Cole
Purpose:Adavosertib (AZD1775), an inhibitor of WEE1 kinase, potentiates replicative stress induced by oncogenes or chemotherapy. Antitumor activity of adavosertib has been demonstrated in preclinical models of pediatric cancer. This phase I trial was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10ac7af709f1c613661298891df3fcff
https://doi.org/10.1158/1078-0432.c.6530348
https://doi.org/10.1158/1078-0432.c.6530348
Autor:
Yael P. Mossé, Brenda J. Weigel, Susan M. Blaney, Peter C. Adamson, Elizabeth Fox, Stacey L. Berg, Keith Wilner, Frank M. Balis, Charles G. Minard, David C. Hall, Stephan D. Voss, Jennifer H. Foster
Purpose:Anaplastic lymphoma kinase (ALK) aberrations are a promising target for patients with neuroblastoma. We assessed the activity of first-generation ALK inhibitor crizotinib in patients with no known curative treatments and whose tumors harbored
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::846be02661708377f2281440378d489e
https://doi.org/10.1158/1078-0432.c.6530406
https://doi.org/10.1158/1078-0432.c.6530406
Autor:
Brenda J. Weigel, Elizabeth Fox, Joel M. Reid, Stacey L. Berg, Stephan D. Voss, Daphne A. Haas-Kogan, John M. Maris, Bruce R. Pawel, Charles G. Minard, Xiaowei Liu, Heba Ijaz, Rachel A. Kudgus, Sharmistha Pal, Kristina A. Cole
S1. Patient Characteristics of eligible (n=37) and MTD/RP2D evaluable (n=27) patients S1B. Diagnosis of eligible (n=37) and MTD/RP2D evaluable (n=27) patients. S2. In Cycle 1, All Hematologic and Non-Hematologic toxicities related to protocol therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9323958b0560e209f384c5b0109ec8d8
https://doi.org/10.1158/1078-0432.22480001.v1
https://doi.org/10.1158/1078-0432.22480001.v1
Autor:
Jonathan D. Wasserman, Joshua D. Schiffman, Stephan D. Voss, Anita Villani, Gail E. Tomlinson, Lisa J. States, Katherine L. Nathanson, Wendy K. Kohlmann, Junne Kamihara, Katherine A. Janeway, Harriet Druker, Ayelet Erez, Surya P. Rednam
Exposures to avoid prior to metanephrine testing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ab7ac29eef799721567ec45d6beffe5
https://doi.org/10.1158/1078-0432.22463313.v1
https://doi.org/10.1158/1078-0432.22463313.v1
Autor:
Jonathan D. Wasserman, Joshua D. Schiffman, Stephan D. Voss, Anita Villani, Gail E. Tomlinson, Lisa J. States, Katherine L. Nathanson, Wendy K. Kohlmann, Junne Kamihara, Katherine A. Janeway, Harriet Druker, Ayelet Erez, Surya P. Rednam
Von Hippel–Lindau disease (vHL) is a hereditary tumor predisposition syndrome that places affected individuals at risk for multiple tumors, which are predominantly benign and generally occur in the central nervous system or abdomen. Although the ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be5c9e35d1118f8700fcd8ce03da9cc
https://doi.org/10.1158/1078-0432.c.6525366
https://doi.org/10.1158/1078-0432.c.6525366